In addition, although IL-4 exhibited a proliferation inhibition effects in vitro of RCC [22, 23], the clinical use of IL-4 as an administrated agent failed to inhibit the progression of RCC and other cancers [24, 25]. Here, IL4 is linked to renal cell carcinoma.